AU673002B2 - Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol - Google Patents

Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Info

Publication number
AU673002B2
AU673002B2 AU49225/93A AU4922593A AU673002B2 AU 673002 B2 AU673002 B2 AU 673002B2 AU 49225/93 A AU49225/93 A AU 49225/93A AU 4922593 A AU4922593 A AU 4922593A AU 673002 B2 AU673002 B2 AU 673002B2
Authority
AU
Australia
Prior art keywords
hmb
cholesterol
ldl
lactone
total cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU49225/93A
Other languages
English (en)
Other versions
AU4922593A (en
Inventor
Steven L. Nissen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iowa State University Research Foundation Inc ISURF
Original Assignee
Iowa State University Research Foundation Inc ISURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU673002(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iowa State University Research Foundation Inc ISURF filed Critical Iowa State University Research Foundation Inc ISURF
Publication of AU4922593A publication Critical patent/AU4922593A/en
Application granted granted Critical
Publication of AU673002B2 publication Critical patent/AU673002B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU49225/93A 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol Ceased AU673002B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94640492A 1992-09-16 1992-09-16
US946404 1992-09-16
PCT/US1993/008695 WO1994006417A1 (en) 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Publications (2)

Publication Number Publication Date
AU4922593A AU4922593A (en) 1994-04-12
AU673002B2 true AU673002B2 (en) 1996-10-24

Family

ID=25484425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49225/93A Ceased AU673002B2 (en) 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Country Status (12)

Country Link
US (1) US5360613A (Direct)
EP (1) EP0660706B1 (Direct)
JP (1) JP3148243B2 (Direct)
AU (1) AU673002B2 (Direct)
BR (1) BR9307035A (Direct)
CA (1) CA2142314C (Direct)
DE (1) DE69327468T2 (Direct)
ES (1) ES2142353T3 (Direct)
FI (1) FI951218A7 (Direct)
NO (1) NO951000D0 (Direct)
NZ (1) NZ256300A (Direct)
WO (1) WO1994006417A1 (Direct)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
AU2620600A (en) * 1999-01-21 2000-08-07 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
JP4166580B2 (ja) * 2001-05-18 2008-10-15 ロンザ ア−ゲ− ３−ヒドロキシ−３−メチル酪酸ナトリウムの固体組成物の製造方法
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
WO2005096846A1 (en) * 2004-03-11 2005-10-20 Wiley Organics, Inc. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
JP5227182B2 (ja) 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
EP3403516A1 (en) 2008-12-09 2018-11-21 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11042605B2 (en) 2009-07-21 2021-06-22 Ccqcc Corp. Method and apparatus for calibration and testing of scientific measurement equipment
US8538727B2 (en) * 2009-07-21 2013-09-17 George S. Cembrowski Method and apparatus for calibration and testing of scientific measurement equipment
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
US8916217B2 (en) 2010-01-29 2014-12-23 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
RU2012125881A (ru) 2010-01-29 2014-03-10 Эбботт Лэборетриз Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция)
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CA2841748C (en) * 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
EP2744489A4 (en) * 2011-08-15 2015-03-18 Abbott Lab PROCESS FOR THE PREPARATION OF HMB AND SALTS FROM THEREOF
EP2773363A1 (en) 2011-11-03 2014-09-10 University of Florida Research Foundation, Inc. Nutritional supplement for weight management
WO2012140276A2 (en) * 2011-11-17 2012-10-18 Lonza Ltd Process for the preparation of 3-hydroxy-3-methylbutyric acid or its calcium salts
PL3733171T3 (pl) 2012-09-10 2024-03-18 Metabolic Technologies, LLC Kompozycje zawierające hmb i atp oraz ich zastosowanie
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
ES2973467T3 (es) 2015-09-16 2024-06-20 Metabolic Tech Llc Composiciones y métodos de uso de beta-hidroxi-beta-metilbutirato (HMB) para mejorar la recuperación de trauma de tejidos blandos
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
ES2899261T3 (es) * 2015-11-19 2022-03-10 Kyowa Hakko Bio Co Ltd Cristales de una sal de un catión monovalente de ácido 3-hidroxiisovalérico y método para producir dichos cristales
BR112018014920A2 (pt) 2016-01-21 2018-12-18 Metabolic Tech Inc métodos de autofagia por modulação, de tratamento ou redução da probabilidade do início de uma condição mediada por autofagia, de tratamento, inibição, redução, diminuição, ou prevenção de um distúrbio relacionado à idade, de modulação da expressão ou atividade de pelo menos um fator de transcrição, de tratamento, prevenção, diminuição, inibição ou redução de uma condição patológica atribuível a um estado de excesso de nutriente, de promoção de longevidade por autofagia por modulação, de aumento da duração de tempo que um mamífero pode levar um estilo de vida ativo sem sofrer de condições associadas com envelhecimento e de prolongamento do período de saúde de um mamífero.
SG11201811493UA (en) 2016-06-24 2019-01-30 Otsuka Pharma Factory Inc Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof
CA3041520A1 (en) 2016-10-21 2018-04-26 Metabolic Technologies, Inc. Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) and probiotics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629449A (en) * 1968-04-22 1971-12-21 Majid Siddiqi Process of combatting hypercholesterolemia
US4764531A (en) * 1986-03-11 1988-08-16 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to laying chickens
US4760090A (en) * 1986-03-11 1988-07-26 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to cattle and sheep
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development

Also Published As

Publication number Publication date
FI951218A0 (fi) 1995-03-15
JPH08501777A (ja) 1996-02-27
AU4922593A (en) 1994-04-12
EP0660706B1 (en) 1999-12-29
ES2142353T3 (es) 2000-04-16
FI951218L (fi) 1995-03-15
DE69327468T2 (de) 2000-05-11
FI951218A7 (fi) 1995-03-15
NZ256300A (en) 1997-06-24
NO951000L (no) 1995-03-15
WO1994006417A1 (en) 1994-03-31
CA2142314A1 (en) 1994-03-31
US5360613A (en) 1994-11-01
CA2142314C (en) 1999-06-01
EP0660706A1 (en) 1995-07-05
BR9307035A (pt) 1999-06-29
NO951000D0 (no) 1995-03-15
JP3148243B2 (ja) 2001-03-19
DE69327468D1 (de) 2000-02-03
EP0660706A4 (Direct) 1995-07-26

Similar Documents

Publication Publication Date Title
AU673002B2 (en) Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol
EP0637239B1 (en) Use of beta-hydroxy-beta-methylbutyric acid for promoting nitrogen retention in humans
JP2992836B2 (ja) 共役リノール酸の投与による動物の体脂肪を減少させる方法
JPH0662758A (ja) バイオマスの利用
EA025256B1 (ru) Композиция, подходящая для лечения нарушений липидного обмена
US6046184A (en) Medicament for treating obesity and improving lipid metabolism
US5240962A (en) Antiobesity and fat-reducing agents
JP2005518353A (ja) オステオポローシス治療のための組成物の製造のためのグルタミン酸塩、グルタミン酸塩誘導体又はグルタミン酸塩代謝物、グルタミン酸塩アナログ或いはそれらの混合物の使用
US7238727B2 (en) Compositions for improving lipid metabolism
EP0662324A1 (en) Use of beta-adrenergic agonists for treating loss of function of striated muscles
US20080027139A1 (en) Use of Alpha-Ketoglutarate and Related Compounds
US5530029A (en) Therapeutic applications of clenbuterol
JPS6299323A (ja) 高脂血症剤
Hayashi et al. Acute inhibition of lipid transport in rat intestinal lymph by ethanol administration
Maclean et al. The effect of high protein diet on renal function
US20240423941A1 (en) Medium chain dicarboxylic acids for the treatment and prevention of diseases and conditions
US6531462B2 (en) Medicament for treating obesity and improving lipid metabolism
Shaklee Research on cholesterol in poultry and eggs in the United States
EP1706105A1 (en) Method of treating type iii hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
Al-Shebib et al. Experimental study of the effects on rabbits of the injectable contraceptive medroxyprogesterone acetate, cholesterol feeding and drug-atherogenic diet combination
HK1056313A (en) Compositions for improving lipid metabolism

Legal Events

Date Code Title Description
GD Licence registered

Name of requester: METABOLIC TECHNOLOGIES, INC.